Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ... Nature medicine 24 (5), 679-690, 2018 | 1551 | 2018 |
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The Lancet Oncology 17 (9), 1283-1294, 2016 | 996 | 2016 |
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ... Clinical Cancer Research 19 (13), 3462-3473, 2013 | 949 | 2013 |
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ... Cancer cell 24 (6), 777-790, 2013 | 815 | 2013 |
PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome MGM Roemer, RH Advani, AH Ligon, Y Natkunam, RA Redd, H Homer, ... Journal of Clinical Oncology 34 (23), 2690, 2016 | 789 | 2016 |
Targetable genetic features of primary testicular and primary central nervous system lymphomas B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ... Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016 | 525 | 2016 |
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma L Nayak, FM Iwamoto, A LaCasce, S Mukundan, MGM Roemer, B Chapuy, ... Blood 129 (23), 3071-3073, 2017 | 407 | 2017 |
Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, ... Journal of Clinical Oncology 37 (6), 481, 2019 | 336 | 2019 |
Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma MGM Roemer, RA Redd, FZ Cader, CJ Pak, S Abdelrahman, J Ouyang, ... Journal of Clinical Oncology 36 (10), 942, 2018 | 314 | 2018 |
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ... Blood 130 (22), 2420-2430, 2017 | 308 | 2017 |
Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24. 1 status MGM Roemer, RH Advani, RA Redd, GS Pinkus, Y Natkunam, AH Ligon, ... Cancer immunology research 4 (11), 910-916, 2016 | 185 | 2016 |
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain M Shi, MGM Roemer, B Chapuy, X Liao, H Sun, GS Pinkus, MA Shipp, ... The American journal of surgical pathology 38 (12), 1715, 2014 | 181 | 2014 |
Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva BE Howitt, HH Sun, MGM Roemer, A Kelley, B Chapuy, E Aviki, C Pak, ... JAMA oncology 2 (4), 518-522, 2016 | 128 | 2016 |
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva BE Howitt, HH Sun, MGM Roemer, A Kelley, B Chapuy, E Aviki, C Pak, ... JAMA oncology 2 (4), 518-522, 2016 | 128 | 2016 |
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease B Chapuy, H Cheng, A Watahiki, MD Ducar, Y Tan, L Chen, MGM Roemer, ... Blood, The Journal of the American Society of Hematology 127 (18), 2203-2213, 2016 | 93 | 2016 |
PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential J Rotman, LAS Den Otter, MCG Bleeker, SS Samuels, AM Heeren, ... Frontiers in immunology 11, 2020 | 70 | 2020 |
Clinical validation of Whole Genome Sequencing for cancer diagnostics P Roepman, E de Bruijn, S van Lieshout, L Schoenmaker, MC Boelens, ... The Journal of Molecular Diagnostics, 2021 | 53 | 2021 |
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment HJ van der Horst, AV de Jonge, IH Hiemstra, AT Gelderloos, DRAI Berry, ... Blood cancer journal 11 (2), 1-8, 2021 | 51 | 2021 |
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency2015 SH/EAHP Workshop Report—Part 2 D De Jong, MGM Roemer, JKC Chan, J Goodlad, D Gratzinger, ... American journal of clinical pathology 147 (2), 153-170, 2017 | 42 | 2017 |
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency2015 SH/EAHP Workshop Report—Part 2 D de Jong, MGM Roemer, JKC Chan, J Goodlad, D Gratzinger, ... American Journal of Clinical Pathology 147 (2), 153-170, 2017 | 42 | 2017 |